

Index

- Acme Markets* case, 80, 94, 95
Act to Prevent Pollution from Ships, 169, 170
AIG, 84–85
Anonymity
 anonymous complaints, investigation of, 108, 117, 118
 Dodd-Frank provisions, 23, 195
 employee surveys, 123, 124
 importance of, 2, 5, 74, 85, 86, 109, 126
 international issues, 121, 122
 IRS whistleblowers, 165
 as part of whistleblower system, 4, 85, 97, 105, 106, 108, 109, 119–123, 127
 Sarbanes-Oxley requirement, 1, 106
 SEC whistleblowers, 23, 195, 199, 200, 205, 250, 251, 253–255
 shell companies, use of, 106, 121, 173
Appeals, SEC determinations, 201, 205, 259–261
Arkell, John, 94
Asia, 122
Attorney-client privilege, 115, 120, 197, 243
Attorney representation
 False Claims Act, 147
 IRS whistleblowers, 165
 SEC whistleblowers, 14, 23, 195, 199, 200, 251, 253, 254
 Bank of America, 82, 83, 85
 Barker, Mary, 180–185
 Bear Stearns, 85
 Bingham, James J., 58, 59
 Birkenfeld, Bradley, 154
Board of directors
 auditors, reliance on, 86–89
 duty to supervise and monitor management, 83, 89
 fiduciary duties, liability for breach of, 89–91
 “head-in-the-sand” approach, 91, 92
 independent directors. *See* Independent directors
 information provided to, reliance on, 82–86
 lack of reporting from executives and lower-level management, 84–86
 liability, 80, 89, 91–93
 overview, 81, 82
 reputation, 4, 79, 80, 83, 90, 104, 110, 111
 systems for detection of illegal behavior, 90, 91
Broker-dealer violations, 21, 22
California False Claims Act, 175, 176
Caremark International, Inc. Derivative Litigation, 90, 91

- Chief executive officers (CEOs)
 board of directors, withholding information from, 82–84, 86, 103, 104
 liability, 79, 80, 91–95
 resume fraud, 84
 retaliation from, 61, 85, 108, 117
 tone at the top, 41, 105, 109, 128, 134, 135
 and whistleblower system, benefits of, 79, 80
- Civil liability, 79, 92, 93, 104, 113
- Collins, Blair, 46
- Commodity Exchange Act, 23, 24, 241
- Communication of whistleblower policy, 109, 127–130
- Compensation plans and impact of whistleblower complaints, 109–111, 114
- Cooper, Cynthia, 69, 71
- Corporate scandals, 2, 80, 82, 84, 86, 87, 90, 104
- Corporations
 criminal liability, 80, 81, 92–97
 reputation, 80, 81, 92, 113, 126, 132
- Costs of investigating complaints, 98
- Criminal liability
 board of directors, 91–93
 chief executive officers (CEOs), 79, 80, 91–95
 corporations, 80, 81, 92–97. *See also* *Caremark International, Inc. Derivative Litigation*; *Glaxo settlement*; *Pfizer settlement*
 and need for whistleblower system, 79
- DeMott, Glenn, 45
- Department of Justice. *See* U.S. Department of Justice (DOJ)
- Director of corporate compliance, 4, 109, 132–134
- Disadvantages of whistleblower system, 97, 98
- Disincentives for internal whistleblowers
 breach of contract suits, 60
 breach of fiduciary duty, 60, 61
 financial, 58, 59
 nonfinancial, 59, 60
 overview, 2, 57, 58
 reinstatement, 62, 65
 retaliation, 61–66, 85. *See also* *Retaliation*
- Dodd-Frank Wall Street Reform and Consumer Protection Act
 accounting standards violations, 20
 anti-retaliation provisions, 179, 180. *See also* *Retaliation*
- Commodity Exchange Act, rewards under, 23, 24
 enactment of, 1
 false financial statements by public companies, 20–22
 federal securities laws, violations of, 15–23, 142, 154
 ineligibility for reward, 14, 15
 original information requirement, 13–15. *See also* *Original information*
 protections for whistleblowers, 23, 179, 180.
See also *Whistleblower protection*
 reinstatement remedy, 62, 65
 Rule 10b-5 (Exchange Act Section 10(b))
 violations, 19
 SEC whistleblower provisions. *See* *Securities and Exchange Commission (SEC)*
 whistleblower provisions, 13, 14
 DOJ. *See* U.S. Department of Justice (DOJ)
- Eckard, Cheryl, 4, 27–30, 33–41, 58, 72, 126, 132
- Edmondson, David J., 84
- Effectiveness of whistleblower policies, 2–4, 109, 123, 124
- Employee compliance training, 109, 124
- Employment contracts, confidentiality clauses in, 60
- Enron, 2, 69–71, 82–83, 86, 87, 90, 104, 115, 116, 126. *See also* *Watkins, Sherron*
- Environmental protection laws, 185
- Ethics Resource Center survey, 61–65
- Executives as whistleblowers, 84, 85, 97, 117–119
- External reporting by internal whistleblowers, 72–74
- External whistleblowers, 5
- False Claims Act
 agencies entitled to bring actions under, 142
 attorney representation, 147
 DOJ intervention in private qui tam actions, 146–149
 false claim defined, 142–144
 Glaxo settlement. *See* *Glaxo settlement*
 history of, 6, 13, 24, 141
 investigations, 147, 148
 penalties and damages, 143
 Pfizer settlement. *See* *Pfizer settlement*
 private qui tam actions, 4, 5, 7, 24, 141–150
 reward provisions, 6, 141, 144–146
 state laws, 173–179
 statute of limitations, 149, 150
- False patent marking, rewards for whistleblowers, 170–172
- Federal Bureau of Investigation (FBI), 71, 72, 126
- Fiduciary duties, 18, 60, 61, 80, 83, 89–91

- Florida False Claims Act, 178, 179
- Foreign Corrupt Practices Act (FCPA), 5, 13, 15–17, 21, 194
- France, 121, 122
- Germany, 121
- Glaxo settlement
 complaint allegations, 28–40
 Eckard, Cheryl, 4, 27–30, 33–41, 58, 72, 126, 132
 FDA procedures, 30, 31
 lessons learned, 40–42
 pharmaceutical industry standards and regulations, 30, 31
 post-termination activities of Eckard, 28, 29
 senior executives, continued employment of, 29, 41
 settlement award, 4, 27, 28, 132
- GlaxoSmithKline (Glaxo)
 settlement. *See* Glaxo settlement
- Stevens, Lauren, indictment of, 91, 92
- Government employees, 185, 186
- Government entities, 21
- Hotlines
 and anonymity, 106, 119–123. *See also* Anonymity
 case outcomes, 97, 98
 customers and vendors, 122, 123
 effectiveness of, assessing, 109, 123, 124
 employee familiarity with, 106, 127–130
 hours of operation, 122
 impact of, 3
 independent administration of, 112, 113
 international issues, 121, 122
 lack of use, 3, 103, 104, 123
 language issues, 122
 methods of communication, 122
 personnel complaints, 113
 spurious complaints, 5, 97, 98
 training, 124
- Hurd, Mark, 112
- Identity, protection of. *See* Anonymity
- Incentives
 importance of, 85, 104, 105, 107, 123
 lack of, 2, 3
 rewards. *See* Rewards for whistleblowers
 statutory, 1, 5, 126, 127, 144, 169–186. *See also* specific statutes
- Independent administration of whistleblower systems, 4, 108, 111–113
- Independent auditors, 86–88, 104, 115
- Independent counsel
 administration of whistleblower system, 4, 112, 113
 authority of board to hire, 110
 investigation of complaints, 41, 107, 108, 112–118, 120
 investigation results, reporting to whistleblower, 109, 115, 124, 125
 investigation of retaliation claims, 131, 132
 and legal privileges, 115, 120
 reporting to board, 112
 reward amount recommendation, 126
 selection of, 116
 and whistleblower anonymity, 120
 whistleblower reports submitted to, 108
 for whistleblowers, 114, 120
- Independent directors
 direct communication with by lower-level management, 84–86, 104
 director of corporate compliance, role of, 132–134
 investigation of complaints, 113–117, 131. *See also* investigations
 reliance on auditors, problems with, 86–89, 104, 111
 reliance on management for information, problems with, 82, 84, 86, 104
 reporting to, 4, 108, 109, 112, 132
 responsibility for whistleblower program, 108–111, 126
 termination of whistleblowers, review of, 132
 whistleblower reports submitted to, 108, 112, 113, 122, 123
- Internal audit
 and administration of whistleblower system, 103, 112, 113
 and DOJ Sentencing Guidelines, 96
 investigation of complaints, 2, 106, 107, 112–114, 118
 reliance on, 2, 86–89, 104, 111
 reporting responsibilities, 4, 88, 89, 132, 133
 WorldCom case, 71
- Internal Revenue Service (IRS)
 private qui tam actions not allowed, 142, 154
 tax administration contracts, use of to protect confidentiality, 165, 166
 tips received, 154
 whistleblowers. *See* IRS whistleblowers
 written whistleblower policy, not-for-profit organizations, 103
- Internal whistleblowers
 described, 5, 57

- Internal whistleblowers (*continued*)
- disincentives. *See* Disincentives for internal whistleblowers
 - external reporting by, 72–74. *See also* Glaxo settlement
 - protection of through formation of entity, 121
 - rewards, 109, 125–127
- Investigations
- anonymity, protecting, 120, 121
 - anonymous complaints, 97, 98, 108, 117, 118
 - False Claims Act, 147, 148
 - by independent counsel, 113–117
 - IRS, 155, 156, 161, 165
 - results of, communicating, 107, 124, 125
 - of retaliation claims, 109, 131, 132
 - spurious complaints, 5, 97, 98, 115, 118
- Investor Advisory Group report, 87, 88
- IRS whistleblowers. *See also* Internal Revenue Service (IRS)
- and FCPA violations, 17
 - Form 211, Application for Award for Original Information, 158–160, 208, 209
 - identity protection, 165
 - ineligibility, 166, 167
 - investigations, 155, 156, 161, 165
 - reporting, Form 211, 158, 159
 - rewards, 4, 153–164
 - right to counsel, 165
 - tax return information, confidentiality of, 165, 166
- Kaiser, Glen, 11, 12, 19
- Kaiser, Karen, 11, 12, 14, 19
- Kopchinski, John, 4, 6, 45–47. *See also* Pfizer settlement
- Kozlowski, Dennis, 82
- Kruszewski, Stefan, 45–47
- Latin America, 122
- Lay, Kenneth, 69, 71, 115
- Lee, Matthew, 83
- Lehman Brothers Holdings Inc., 2, 22, 83, 88, 104
- Limited liability company (LLC), 121
- Limited partnerships (LPs), 121
- Lloyd–La Follette Act of 1912, 185
- Lonchar, Kenneth, 84
- Madoff, Bernard, 12, 13, 18, 107, 118, 119
- Markopolos, Harry, 12, 13, 57, 107, 118, 119, 121, 174
- Medicaid fraud, 13, 27, 32, 144, 173–178
- Medicare fraud, 13, 32, 143, 144
- Merrill Lynch, 61, 82, 83, 85, 126
- Microsoft Corp., 11, 12, 19
- Military Whistleblower Protection Act, 186
- Mitchell, Brian, 84
- Morse, Gene, 71
- Motivation of whistleblower, 108, 118, 119. *See also* Rewards for whistleblowers
- New York False Claims Act, 174, 175
- Notification and Federal Employee Antidiscrimination and Retaliation Act of 2002 (No FEAR Act), 186
- Occupational Safety and Health Administration (OSHA), 182, 186
- Ombudsman, 4, 41, 107, 108, 110, 112, 113, 118. *See also* Independent counsel
- \$1 million threshold for SEC actions, 202, 254–256
- O’Neal, Stan, 61, 82, 83
- Original information, 13–15, 21, 23, 24, 158, 172, 190–193, 195–199
- Ostracism of whistleblowers, 59
- Papow, Jeffrey P., 84
- Park, Charles, 80
- Park, Eugene, 85
- Park, John R., 94, 95
- Pequot Capital Management, Inc., 11, 12, 19
- Pfizer settlement
- awards to whistleblowers, 4, 45, 46
 - complaint allegations, 48–51
 - lessons learned, 51–53
 - settlement amount, 4, 45
 - whistleblowers, 45–47. *See also* Kopchinski, John
- Pharmacia & Upjohn Company, Inc. *See* Pfizer settlement
- Phillips & Cohen (law firm), 174
- Private companies, 21
- Psychological pressures, 59, 60
- Public Company Accounting Oversight Board (PCAOB), 87, 190, 192, 193, 198, 245
- Rainero, Ronald, 45
- Reasons for adoption of whistleblower system, 79, 80, 85, 92, 98
- Reinstatement of whistleblowers, 62, 65
- Renault SA, 110, 116, 117
- Reputation
- board members, 4, 79, 80, 83, 90, 104, 110, 111
 - corporation, 80, 91, 92, 113, 126, 132

- executives, 4, 79, 80
- whistleblowers, 58, 66
- Responsible Corporate Officer doctrine, 93–95
- Retaliation. *See also* Whistleblower protection
 - from CEOs, 61, 85, 108, 117
 - claims, investigation of, 109, 131, 132
 - as disincentive, 60–66, 85
 - Dodd-Frank anti-retaliation provisions, 179, 180
 - and external reporting by internal whistleblowers, 72–74
 - SEC anti-retaliation provisions, 206
 - survey on, 61, 62
 - types of, 63–66
 - against women, 69, 72
- Rewards for whistleblowers
 - Act to Prevent Pollution from Ships, 169, 170
 - amount of, 5, 126
 - Commodity Exchange Act, 23, 24
 - Dodd-Frank provisions for, 5, 14, 15
 - False Claims Act provisions, 6, 141, 144–146
 - false patent marking, 170–172
 - internal whistleblowers, 125–127
 - IRS whistleblowers, 4, 153–164
 - meaningful rewards, 126, 127
 - overview, 4, 5
 - Securities and Exchange Commission (SEC), 5, 190–194, 196–204, 240–250, 253–259, 261, 262
 - state false claims statutes, 173–179
 - U.S. Department of Justice (DOJ), 21
 - U.S. Tariff Act of 1930, 172, 173
 - whistleblower system, 109, 125–127
- Rowley, Coleen, 69, 71, 72
- Sanberg, Arthur J., 11, 12
- Sarbanes-Oxley Act of 2002 (SOX)
 - audit committee responsibilities, 109
 - Barker* anti-retaliation case, 180–185
 - and financial crisis of 2007-2009, 87
 - monetary sanctions, 246, 255
 - and multinational corporations, 121
 - PCAOB, establishment of, 87
 - problems with current whistleblower systems, 104–107, 127
 - whistleblower protection, 1, 90, 185
- Securities and Exchange Commission (SEC)
 - anti-retaliation provisions, 206
 - appeals, 201, 205, 259–261
 - attorney representation, 14, 23, 195, 199, 200, 251, 253, 254
 - broker-dealer registration, 21, 22
 - communications with individuals, 262, 263
 - and compliance with company's internal program, 204, 205
 - eligibility, 251–253
 - enforcement actions, impact of on stock price, 81
 - Form TCR, 199, 200, 212–228
 - Form WB-APP, 200, 230–238
 - identity protection, 205, 250, 251
 - Investor Protection Fund, 194
 - no amnesty, 252
 - \$1 million threshold, 202, 254–256
 - Pequot Capital Management case, 11, 12
 - procedure for submitting information, 253–255
 - qualifying to receive award, guide to, 196–201
 - rights and remedies of whistleblowers, non-waiver of, 205
 - securities laws, violations of, 15–23
 - tips received, 189
 - whistleblower anonymity, 23, 195, 199, 200, 205, 250, 251, 253–255
 - whistleblower awards, 5, 190–194, 196–204, 240–250, 253–259, 261, 262
 - whistleblower defined, 189, 240
 - whistleblower rules (Section 21F of Securities Exchange Act), 200, 239–263
 - Securities Exchange Act of 1934
 - false financial statements, 20, 21
 - FCPA violations, 15–17
 - private companies, applicability to, 21
 - whistleblower rules (Section 21F), 200, 239–263
 - Securities law violations, 15–23, 142, 154. *See also* Securities and Exchange Commission (SEC)
 - Sentencing Guidelines, 96, 97, 133, 135
 - Shareholder actions, 80
 - Shareholder wealth, 79–81, 91, 98, 113
 - Shell companies, 106, 121, 173
 - Spencer, Dana, 46
 - Spurious complaints, 5, 97, 98, 115, 118
 - State laws, 13, 173–179, 185
 - Stevens, Lauren, 91–92
 - Tax fraud. *See* Internal Revenue Service (IRS); IRS whistleblowers
 - Termination of whistleblowers, 132. *See also* Retaliation
 - Texas False Claims Act, 176–178
 - Tone at the top, 41, 105, 109, 128, 133–135
 - Training for employees, 124
 - Tyco, 82

- UBS, 21, 22, 154, 180–185
- U.S. Department of Justice (DOJ)
- FCPA violations, 21
 - Glaxo case. *See* Glaxo settlement
 - intervention in private qui tam actions, 146–149
 - officers and directors, actions against, 80, 91, 92
 - Pfizer case. *See* Pfizer settlement
 - rewards, 21
 - securities law violations, 142, 154
 - Sentencing Guidelines, 96, 97, 133–135
- U.S. Tariff Act of 1930, 172, 173
- Vinson & Elkins, 115, 116
- Watkins, Sherron, 69–71, 82, 115, 116, 126
- Whistleblower policy, elements of, 108–134
- Whistleblower protection
- anonymity. *See* Anonymity
 - Commodity Exchange Act provisions, 23, 24
 - company policies, 2, 3
 - Dodd-Frank provisions, 23, 179, 180
 - entities, use of, 106, 121, 173
 - federal statutes, 185, 186
 - foreign countries, 179
 - identity protection. *See* Anonymity
 - misuse of by employees, 5, 119
 - and reinstatement, 62, 65
 - from retaliation, 131, 132, 174, 177, 179–186, 206, 240
 - Sarbanes-Oxley, 180–185
- Whistleblower Protection Act of 1989, 186
- Whistleblower systems
- about, 103, 104
 - anonymous complaints, treatment of, 108, 117, 118
 - assessments of effectiveness, 109, 123, 124
 - Caremark standard, 90, 91
 - communication of policy, 109, 127–130
 - employee compliance training, 109, 124
 - identity protection, 109, 119–123
 - independent administration of, 108, 111–113
 - independent directors, responsibilities of, 108–111
 - initial steps for establishing, 107, 108
 - investigation of complaints, 108, 109, 113–117, 124, 125
 - policy, elements of, 108–134
 - problems with, 104–107
 - reporting by corporate compliance director to independent directors, 109, 132–134
 - retaliation claims, investigation of, 109, 131, 132
 - rewards, 109, 125–127
 - sanctions for involvement in illegal group activity, 109, 130, 131
 - tone at the top, 109, 133, 135
- Winokur, Herbert S., Jr. (“Pug”), 82, 83, 86
- Women whistleblowers
- Cooper, Cynthia, 69, 71
 - and external reporting by internal whistleblowers, 72–74
 - retaliation, 62, 69, 72
 - Kowley, Coleen, 69, 71, 72
 - Watkins, Sherron, 69–71, 82, 115, 116, 126
- Work product doctrine, 115, 149
- WorldCom, 2, 71, 86, 87, 89. *See also* Cooper, Cynthia
- Wright-Patterson Air Force Base study, 65, 66, 72
- Xerox, 58, 59
- Zarella, Ronald, 84
- Zilkha, David E., 11, 12, 19
- Zilkha, Karen. *See* Kaiser, Karen